Cost-effectiveness analysis of the Lyme disease vaccine

Arthritis and Rheumatism

Volumn 46, Issue 6, 2002, Pages 1651-1660

  Hsia, Elizabeth C ^a   Chung, James B ^a   Schwartz, J Sanford ^a   Albert, Daniel A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LYME DISEASE VACCINE;

ANAPHYLAXIS; ARTICLE; CHILL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG SAFETY; FEVER; HUMAN; INCIDENCE; KIDNEY DISEASE; LYME DISEASE; MONTE CARLO METHOD; PANCYTOPENIA; POPULATION MODEL; PRIORITY JOURNAL; RISK MANAGEMENT; VACCINATION;

COST-BENEFIT ANALYSIS; ENDEMIC DISEASES; HUMANS; IMMUNIZATION, SECONDARY; INCIDENCE; LYME DISEASE; LYME DISEASE VACCINES; RISK FACTORS; SENSITIVITY AND SPECIFICITY; UNITED STATES;

EID: 0036269163     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.10270     Document Type: Article

References (46)

1. Surveillance for Lyme disease - United States, 1992-1998
2. Lyme disease
3. Lyme disease - United States, 1996
4. Lyme disease vaccines
5. Vaccination as a modality to prevent Lyme disease: A status report
6. Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant
7. Lyme disease
8. Evaluation of reactogenicity and immunogenicity of booster doses of LYMErixTM, recombinant L-Osp-A vaccine against Lyme disease (LD)
9. The Recombinant Outer-Surface Protein A Lyme Disease Vaccine Study Consortium. A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease
10. A cost-of-illness study of Lyme disease in the United States
11. Prevention of Lyme disease after tick bites: A cost-effectiveness analysis
12. Summary of notifiable diseases, United States, 1998
13. Test-treatment strategies for patients suspected of having Lyme disease: A cost-effectiveness analysis
14. Recommendations for the use of Lyme disease vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
15. The Lyme disease vaccine: Conception, development, and implementation
16. Practice guidelines for the treatment of Lyme disease
17. Lyme disease vaccine
18. Empiric parenteral antibiotic treatment of patients with fibromyalgia and fatigue and a positive serologic result for Lyme disease: A cost-effectiveness analysis
19. Rapid emergence of a focal epidemic of Lyme disease in coastal Massachusetts
20. Occupation risk of Lyme disease in endemic areas of New York state
21. Lyme disease in outdoor workers: Risk factors, preventive measures, and tick removal methods
22. Musculoskeletal and neurologic outcomes in patients with previously treated Lyme disease
23. Long-term outcomes of persons with Lyme disease
24. Predisposing factors for individuals' Lyme disease prevention practices: Connecticut, Maine, and Montana
25. The geographic spread and temporal increase of the Lyme disease epidemic
26. Temporal correlations between tick abundance and prevalence of ticks infected with Borrelia burgdorferi and increasing incidence of Lyme disease
27. Estimation of the incidence of Lyme disease
28. Prevention of Lyme disease: A review of the evidence
29. Prophylaxis with single-dose doxycycline for the prevention of Lyme disease after an Ixodes scapularis tick bite
30. The cost-effectiveness of vaccination against Lyme disease
31. The cost effectiveness of vaccinating against Lyme disease
32. The cost-effectiveness of misoprostol in preventing serious gastrointestinal events associated with the use of nonsteroidal antiinflammatory drugs
33. Cost-effectiveness of infective endocarditis prophylaxis for mitral valve prolapse with or without a mitral regurgitant murmur
34. Identification of LFA-1 as a candidate autoantigen in treatment-resistant Lyme arthritis
35. Patients sue over effects of vaccine
36. Lyme vaccine safety data reported to the vaccine adverse event reporting system (VAERS) of the USA from the first year of use
37. Anxiety and persistence of Lyme disease
38. The Lyme disease controversy: Social and financial costs of misdiagnosis and mismanagement
39. The consequences of overdiagnosis and overtreatment of Lyme disease: An observational study
40. The public health impact of Lyme disease in Maryland
41. Tick bites and Lyme disease in an endemic setting: Problematic use of serologic testing and prophylactic antibiotic therapy